On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...